WELL Health Technologies has announced plans for its subsidiary, WELLSTAR Technologies Corp., to become a publicly listed company on the TSX Venture Exchange. This strategic move is supported by a concurrent private placement expected to raise approximately C$50 million. The transaction aims to establish WELLSTAR as an independent entity, unlocking its value while fueling its next phase of growth in the healthcare technology sector.
Strategic Vision for Growth
Hamed Shahbazi, CEO of parent company WELL Health, highlighted the transaction as a key milestone in unlocking the value of its digital assets. WELL will remain a significant controlling shareholder, maintaining a symbiotic relationship where its clinical network strengthens WELLSTAR’s product offerings. This public listing is designed to provide WELLSTAR with enhanced strategic flexibility and greater access to capital for future expansion.
WELLSTAR has demonstrated impressive performance, with a historical three-year organic revenue compound annual growth rate exceeding 20%. The company, which serves over 40% of healthcare providers in Canada, projects approximately $95 million in revenue for 2026. This strong financial footing and market penetration position it as a formidable player in the pure-play healthcare technology space.
Financing and Transaction Structure
The C$50 million concurrent financing is being co-led by prominent financial institutions including TD Securities Inc., RBC Capital Markets, and Stifel. Proceeds are earmarked for strategic acquisitions, AI-driven product innovation, and other organic growth initiatives. This capital injection will significantly bolster WELLSTAR’s capacity to expand its platform and solidify its market leadership.
The public listing will be achieved through an amalgamation agreement with 1587818 B.C. Ltd., with the resulting entity continuing WELLSTAR's business. Investors in the financing will initially receive subscription receipts at a price of C$10.00 each. These receipts will automatically convert into freely tradeable subordinate voting shares upon the transaction's completion, which is anticipated around mid-September 2026.
Future Governance and Leadership
Following the transaction, the new public company will feature a dual-class share structure, allowing WELL Health to retain majority voting control. This arrangement ensures continued strategic alignment and reinforces WELL’s long-term commitment as both a major shareholder and a key customer. The structure is designed to provide stability while allowing public investors to participate in WELLSTAR's growth journey.
Leadership continuity is a core component of the plan, with Amir Javidan set to continue as Chief Executive Officer of the newly public company. WELL's CEO, Hamed Shahbazi, will serve as Chairman of the Board, guiding its strategic direction. The existing executive team is also expected to remain, ensuring a seamless transition and consistent operational execution post-listing.
WELLSTAR’s impending public debut, fortified by a substantial C$50 million financing, marks a pivotal moment for the Canadian digital health landscape. This strategic initiative is poised to accelerate the company’s innovation in AI and expand its acquisition pipeline. Ultimately, the move positions WELLSTAR to enhance its support for healthcare providers and deliver long-term value to its new public shareholders.